Its vocal biomarkers are already being used to gauge the effect of drug treatments for dementia, including in the phase 2 TAURIEL trial of Roche/AC Immune's tau protein-targeted antibody semorinemab.

Biogen abandoned the development of its antibody candidate gosuranemab in 2021, and Roche/AC Immune’s semorinemab missed the mark in the phase 2 TAURIEL trial in early-stage Alzheimer’s in 2020.